Your browser doesn't support javascript.
loading
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
Fallah, Jaleh; Xu, Jianjin; Joeng, Hee-Koung; Weinstock, Chana; Heiss, Brian L; Maguire, William F; Gao, Xin; Cheng, Joyce; Chang, Elaine; Agrawal, Sundeep; Fiero, Mallorie H; Pazdur, Richard; Kluetz, Paul G; Amiri-Kordestani, Laleh; Suzman, Daniel L.
Affiliation
  • Fallah J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Xu J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Joeng HK; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Weinstock C; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Heiss BL; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Maguire WF; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Gao X; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Cheng J; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Chang E; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Agrawal S; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Fiero MH; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Pazdur R; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Kluetz PG; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD.
  • Amiri-Kordestani L; Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Suzman DL; Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD.
JCO Precis Oncol ; 8: e2400354, 2024 Aug.
Article in En | MEDLINE | ID: mdl-39208375
ABSTRACT
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Ataxia Telangiectasia Mutated Proteins / Checkpoint Kinase 2 / Poly(ADP-ribose) Polymerase Inhibitors / Circulating Tumor DNA / Mutation Limits: Aged / Humans / Male / Middle aged Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Ataxia Telangiectasia Mutated Proteins / Checkpoint Kinase 2 / Poly(ADP-ribose) Polymerase Inhibitors / Circulating Tumor DNA / Mutation Limits: Aged / Humans / Male / Middle aged Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article Country of publication: